Joanne Kurtzberg, MD
Pediatric Hematology-Oncology · Durham, NCNPI 1437212206
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $53,228 of the $72,182 with a category attached, or 73.7%. 5 manufacturers reported payments, led by Mesoblast, Inc. at 39.1% of the total. 2025 is the largest year on record at $45,748, 7.6 times the $6,000 reported in 2019. Among pediatric hematology-oncology clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 41 payments — averaging $1760.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mesoblast, Inc.$28K
- National Marrow Donor Program$22K
- Merck$13K
- Celularity Inc.$6K
- Gamida Cell Inc.$3K
What the payments were for
- Consulting fees$53,22874%
- Speaking & faculty fees$5751%
- Grants$1,0001%
- Travel & lodging$15,71622%
- Food & beverage$1,4062%
- Gifts$2570%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mesoblast, Inc. | 3 | $28,218 |
| National Marrow Donor Program | 20 | $22,174 |
| Merck | 15 | $12,750 |
| Celularity Inc. | 2 | $6,000 |
| Gamida Cell Inc. | 1 | $3,040 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$72,182 in reported general payments places this provider in the 90th percentile of 57 pediatric hematology-oncology providers in North Carolina.
See all pediatric hematology-oncology providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Baclofen | 13 | $89 |
| Olanzapine | 12 | $57 |
| Lorazepam | 12 | $45 |
Paid to pharmacies, not to this prescriber.
Other pediatric hematology-oncology in Durham
- Kris MahadeoDurham$67K
- Jennifer RothmanDurham$42K
- Jennifer JaroscakDurham$22K
- John StrouseDurham$18K
- Paul SzabolcsDurham$14K
- Cassandra MoranDurham$14K
- Timothy DriscollDurham$9K
- Susan KreissmanDurham$7K
- Juhi JainDurham$4K
- Andrea BauchatDurham$558
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.